Clinical Pharmacokinetics and Pharmacodynamics of Cediranib

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) Jonathan A Ledermann et al.   LANCET

Cediranib in ovarian cancer: state of the art and future perspectives

(2016) Ilary Ruscito et al.   TUMOR BIOLOGY

A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors

(2015) Mark W. Kieran et al.   CHILDS NERVOUS SYSTEM

Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma

(2014) I. Judson et al.   CLINICAL CANCER RESEARCH

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29

(2013) S.A. Laurie et al.   EUROPEAN JOURNAL OF CANCER

Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment

(2012) Carla M.L. van Herpen et al.   ANTI-CANCER DRUGS

Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours

(2012) U. Lassen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study

(2012) Peter Mulders et al.   EUROPEAN JOURNAL OF CANCER

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

(2011) F A Raja et al.   BRITISH JOURNAL OF CANCER

Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer

(2011) Taroh Satoh et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer

(2011) Taroh Satoh et al.   INVESTIGATIONAL NEW DRUGS

Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family

(2011) S. R. Brave et al.   MOLECULAR CANCER THERAPEUTICS

A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics

(2010) Claire L. Mitchell et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

In Vitro Hepatic Metabolism of Cediranib, a Potent Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor: Interspecies Comparison and Human Enzymology

(2010) T. Schulz-Utermoehl et al.   DRUG METABOLISM AND DISPOSITION

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours

(2010) Hester van Cruijsen et al.   EUROPEAN JOURNAL OF CANCER

Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study

(2010) Patricia LoRusso et al.   INVESTIGATIONAL NEW DRUGS

A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors

(2010) Elizabeth Fox et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

(2009) Noboru Yamamoto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-Fluorouracil in Patients with Advanced Colorectal Cancer

(2009) E. Chen et al.   CLINICAL CANCER RESEARCH

Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma

(2009) Jörg Dietrich et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors

(2009) Marlies H.G. Langenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis

(2008) C. A. Heckman et al.   CANCER RESEARCH

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

(2008) Glenwood Goss et al.   EUROPEAN JOURNAL OF CANCER

Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group

(2008) Scott A. Laurie et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

(2008) T. P. Padera et al.   MOLECULAR CANCER THERAPEUTICS